Abstract
The number of effective cytotoxic agents for the treatment of patients with metastatic adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy. For the subgroup of patients with inoperable gastrointestinal stromal tumour (GIST), progress has been made via the rapid development and approval of the targeted therapy imatinib. Small round cell tumours (SRCTs), such as Ewing’s sarcoma/primitive neuroectodermal tumour, desmoplastic SRCT and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies, which are treated with multimodality, dose-intensive, neoadjuvant protocols regardless of size or overt metastatic disease. Most other high-grade (grading >I), so-called ‘adult type’, soft tissue sarcomas such as fibrosarcoma, liposarcoma, pleomorphic and synovial sarcomas are treated with an anthracycline-based regimen with or without ifosfamide as front-line therapy. In relapsed ‘adult type’ soft tissue sarcomas, trofosfamide, gemcitabine and trabectedin (ecteinascidin 743) appear to be drugs associated with some activity and an acceptable toxicity profile. A high activity has been reported for the taxanes, in particular for paclitaxel, in vascular sarcomas located in the scalp or face and in Kaposi’s sarcoma. It is interesting to note that the different drugs have particular effects in distinct subtypes of soft tissue sarcoma; however, it should be taken into account that the number of patients included in the phase II trials is limited. The role of the newer agents (e.g. epothilones, brostallicin) is currently undefinable. Targeted therapy inhibiting vascular endothelial growth factor receptor, epidermal growth factor receptor, RAF kinase, c-KIT or platelet-derived growth factor receptors will continue to be tested in GIST patients refractory to imatinib and in other sarcoma histologies.
Similar content being viewed by others
References
Patel SR. New agents in the treatment of soft-tissue sarcomas. Expert Opin Investig Drugs 2000; 9: 1545–51
Patel SR, Chu P, Vadhan-Raj S. Differential responsiveness of leiomyosarcoma (leio) arising at different sites to doxorubicin-based chemotherapy [abstract]. Proc Am Assoc Cancer Res 1997; 38: 7
Bertuzzi A, Castagna L, Nozza A, et al. High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 2002; 20: 2181–8
Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996; 14: 1526–31
Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5: 840–50
Lopez M, Vici P, Di Lauro L, et al. Increasing single epirubicin doses in advanced soft tissue sarcomas. J Clin Oncol 2002; 20: 1329–34
Cure H, Krakowski I, Adenis A, et al. Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group. Eur J Cancer 1998; 34: 422–3
Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003; (3): CD003293
Bokemeyer C, Franzke A, Hartmann JT, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80: 1221–7
Frustaci S, Buonadonna A, Galligioni E, et al. Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. J Clin Oncol 1997; 15: 1418–26
Reichardt P, Tilgner J, Hohenberger P, et al. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998; 16: 1438–43
Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993; 11: 15–21
Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21: 317–21
Benjamin RS, Legha SS, Patel SR, et al. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the MD Anderson experience. Cancer Chemother Pharmacol 1993; 31 Suppl. 2: S174–9
Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 1976; 60: 199–203
Balcerzak SP, Benedetti J, Weiss GR, et al. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas: a Southwest Oncology Group study. Cancer 1995; 76: 2248–52
Gallup DG, Blessing JA, Andersen W, et al. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2003; 89: 48–51
Fata F, O’Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86: 2034–7
van Hoesel QG, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult: EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994; 5: 539–42
Kostler WJ, Brodowicz T, Attems Y, et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol 2001; 12: 1281–8
Edmonson JH, Ebbert LP, Nascimento AG, et al. Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 1996; 19: 574–6
Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000; 18: 2081–6
Okuno S, Geyer SM, Maples WJ, et al. Phase 2 study of epothilone B analog (BMS-247550) in soft tissue sarcomas: an interim report [abstract no. 1645]. Proc Am Soc Clin Oncol 2002; 21: 412a
Spath-Schwalbe E, Genvresse I, Koschuth A, et al. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000; 11: 325–9
Svancarova L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38: 556–9
Okuno S, Edmonson J, Mahoney M, et al. Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002; 94: 3225–9
Okuno S, Ryan LM, Edmonson JH, et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003; 97: 1969–73
Hartmann JT, Oechsle K, Huober J, et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated advanced soft tissue sarcoma [abstract no. PO878]. J Cancer Res Clin Oncol 2004; 130: S192
Amodio A, Carpano S, Manfredi C, et al. Gemcitabine in advanced stage soft tissue sarcoma: a phase II study [in Italian]. Clin Ter 1999; 150: 17–20
Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22: 890–9
Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22: 1480–90
Hartmann JT, Oechsle K, Mayer F, et al. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 2003; 23(2C): 1899–901
Kollmannsberger C, Brugger W, Hartmann JT, et al. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 1999; 10: 453–6
Blomqvist C, Wiklund T, Pajunen M, et al. Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. Cancer Chemother Pharmacol 1995; 36: 263–5
Woll PJ, Judson I, Lee SM, et al. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999; 35: 410–2
Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003; 98: 2693–9
Budd GT, Rankin C, Hutchins LF, et al. Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study: Southwest Oncology Group. Invest New Drugs 2002; 20: 129–32
Reichardt P, Oechsle K, Pink D, et al. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 2003; 21: 481–6
Saylors III RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001; 19: 3463–9
Hosono A, Makimoto A, Kawamoto H, et al. A retrospective analysis in safety and efficacy of protracted administration of irinotecan for patients with small round cell sarcomas relapsed after stem cell transplantation (SCT) [abstract no. 3269]. Proc Am Soc Clin Oncol 2003; 22: 813
Pappo AS, Lyden E, Breitfeld PP, et al. Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma (RMS): a phase II window trial from the Soft Tissue Sarcoma Committee (STS) of the Children’s Oncology Group (COG) [abstract no. 1570]. Proc Am Soc Clin Oncol 2002; 21: 393
De Angelo D, Naujoks R, Manola J, et al. Phase II study of irinotecan (CPT-11) in relapsed or refractory soft tissue sarcoma (STS) [abstract no. 2186]. Proc Am Soc Clin Oncol 2000; 19: 555a
Patel SR, Beach J, Papadopoulos N, et al. Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 2003; 97: 2848–52
Fidias P, Demetri GD, Harmon D. Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/Dana Farber/Partner’s Cancercare Study [abstract no. 1977]. Proc Am Soc Clin Oncol 1998; 17: 513a
Blay JY, Judson I, Rodenhuis S, et al. Phase II study of raltitrexed (‘Tomudex’) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anticancer Drugs 1999; 10: 873–7
Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20: 2824–31
Pivot X, Chevreau C, Cupissol D, et al. Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma. Am J Clin Oncol 2002; 25: 561–4
Casanova M, Ferrari A, Spreafico F, et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 2002; 94: 3263–8
Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001; 19: 3483–9
Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543–9
Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients: preliminary evidence of activity. J Clin Oncol 2001; 19: 1248–55
Demetri GD. ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 2002; 13 Suppl. 1: S7–9
Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002; 50: 309–19
Takahashi N, Li WW, Banerjee D, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001; 7: 3251–7
Leahy MG, Blay JY, le Cesne A, et al. EORTC 62011: phase II trial of brostallicin for soft tissue sarcoma [abstract no. 694]. Eur J Cancer Suppl 2003; 1(5): S209
Stevens MF, Hickman JA, Stone R, et al. Antitumor imidazotetrazines. 1: synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4 (3 H)-one, a novel broad-spectrum antitumor agent. J Med Chem 1984; 27: 196–201
Tsang LL, Quarterman CP, Gescher A, et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991; 27: 342–6
Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846–52
Muro XD, Pousa AL, Buesa JM, et al. Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcoma (STS): a phase II trial of the Spanish Group for Research on Sarcomas (GEIS) [abstract no. 1412]. Proc Am Soc Clin Oncol 2001; 20: 873
O’Reilly S, Rowinsky EK, Slichenmyer W, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14: 3062–73
Bramwell VH, Eisenhauer EA, Blackstein M, et al. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 1995; 6: 847–9
Wall ME, Wani MC, Natschke SM, et al. Plant antitumor agents: 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminata Decne: total synthesis and biological activity. J Med Chem 1986; 29(8): 1553–5
Kharbanda S, Rubin E, Gunji H, et al. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res 1991; 51: 6636–42
Natelson EA, Giovanella BC, Verschraegen CF, et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann N Y Acad Sci 1996; 803: 224–30
Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001; 23: 215–20
Tolcher AW, Eckhardt SG, Kuhn J, et al. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 2001; 19: 2937–47
Bramwell VH, Morris D, Ernst DS, et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorabicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 2002; 8: 383–93
Maki R, Kraft A, Demetri GD, et al. A phase II multicenter study of proteasome inhibitor PS-341 (LDP-341, bortezomib) for untreated recurrent or metastatic soft tissue sarcoma (STS); CTEP study 1757 [abstract no. 3291]. Proc Am Soc Clin Oncol 2003; 22: 819
Schoffski P, Thate B, Beutel G, et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 2004 Apr; 15(4): 671–9
Debrock G, Vanhentenrijk V, Sciot R, et al. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89: 1409–12
Li W, Fan J, Bertino JR. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorabicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 2001; 61: 2579–82
Tomek S, Koestler W, Horak P, et al. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer 2003; 39: 1318–29
Acknowledgements
We acknowledge the excellent assistance of Gabi Jany in the preparation of this manuscript.
The authors have no conflicts of interest directly relevant to the content of this review. No sources of funding were used in the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hartmann, J.T., Patel, S. Recent Developments in Salvage Chemotherapy for Patients with Metastatic Soft Tissue Sarcoma. Drugs 65, 167–178 (2005). https://doi.org/10.2165/00003495-200565020-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200565020-00002